Recombinant DNA technology has played a pivotal role in advancing protein-based therapies, thereby transforming the pharmaceutical industry. However, progressing from a promising drug candidate to a commercialized productrequires a great deal of time and effort. Legacy BioDesign was established with the primary objective of delivering high-quality support in terms of formulation and assay development of biopharmaceuticals. Notably distinct from the majority of contract research organizations (CROs), Legacy is steadfast in its commitment to fostering trust-based relationships with our clients, ensuring meticulous and efficient execution of projects. At Legacy, we value trustworthiness, quality, and reliability, which are held in as high regard as our technical proficiency. Legacy is prepared to collaborate closely with your organization to expedite the development of formulations and assays. One overarching challenge lies in obtaining the maximal of information while conserving material. Consequently, Legacy employs multivariate statistical methods to extract information from every screening study that we perform.

Our core focus is centered on devising strategies that facilitate the efficient transition of protein products from the laboratory to a clinical candidate to the commercial market. Legacy can be your preferred CRO partner for tasks ranging from peptide and protein formulation to assay development, process optimization, drug delivery expertise. We invite you to contact us, so we can discuss our expertise and extensive experience.